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Abstract
Background: The diagnosis of ventilator-associated pneumonia (VAP) remains time-consuming and costly, the clinical
tools lack specificity and a bedside test to exclude infection in suspected patients is unavailable. Breath contains
hundreds to thousands of volatile organic compounds (VOCs) that result from host and microbial metabolism as well
as the environment. The present study aims to use breath VOC analysis to develop a model that can discriminate
between patients who have positive cultures and who have negative cultures with a high sensitivity.
Methods/design: The Molecular Analysis of Exhaled Breath as Diagnostic Test for Ventilator-Associated Pneumonia
(BreathDx) study is a multicentre observational study. Breath and bronchial lavage samples will be collected from 100
and 53 intubated and ventilated patients suspected of VAP. Breath will be analysed using Thermal Desorption – Gas
Chromatography – Mass Spectrometry (TD-GC-MS). The primary endpoint is the accuracy of cross-validated prediction
for positive respiratory cultures in patients that are suspected of VAP, with a sensitivity of at least 99% (high negative
predictive value).
Discussion: To our knowledge, BreathDx is the first study powered to investigate whether molecular analysis of breath
can be used to classify suspected VAP patients with and without positive microbiological cultures with 99% sensitivity.
Trial registration: UKCRN ID number 19086, registered May 2015; as well as registration at www.trialregister.nl under
the acronym ‘BreathDx’ with trial ID number NTR 6114 (retrospectively registered on 28 October 2016).
Keywords: Ventilator-associated pneumonia, Breath analysis, Volatile organic compounds, Metabolomics,
Sensitivity, Specificity
Background
Ventilator-associated pneumonia (VAP) is a frequent
complication of mechanical ventilation in the Intensive
Care Unit (ICU) [1–3] and the associated morbidity re-
sults in substantial healthcare costs [4, 5]. The diagnosis
of VAP remains challenging as clinical, laboratory and
radiological parameters are sensitive but non-specific for
VAP and suffer from high inter-rater variability [6, 7]. A
lower respiratory tract sample [bronchoalveolar lavage
(BAL), endotracheal aspirate or protected specimen
brush sample] is recommended for microbiological
confirmation of clinically suspected VAP [8], but these
results take days to become available and the procedures
cannot be repeated frequently due to their invasiveness.
As a result of this delay, patients are overtreated with
antibiotics, as empiric antibiotic treatment is initiated
immediately after obtaining a lower respiratory tract
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sample. Subsequent microbiological results help to tailor
and deescalate antibiotic treatment [9], so the lower
respiratory tract sample continues to be of crucial im-
portance for diagnosing VAP.
There is need for a less invasive and more time-efficient
diagnostic technique that ultimately reduces the amount
of antibiotics used to treat suspected VAP. Clinical scoring
systems, like the Clinical Pulmonary Infection Score
(CPIS) [10] and biomarkers have been studied as means to
exclude VAP, but so far these attempts have not resulted
in a test that is suitable for current ICU practice [11–15].
Exhaled breath contains volatile organic compounds
(VOCs); small volatile molecules that result from
host or bacterial metabolism or are contaminants
from the environment [16, 17]. Exhaled VOC profiles
have been shown to differentiate between many dif-
ferent disease states and may therefore qualify as
non-invasive biomarkers [18–21]. Capture of VOCs
and exhaled breath analysis has proven to be safe
and reliable in mechanically ventilated critically ill
patients [22–24]. Data from in-vitro experiments sug-
gest that the presence of bacteria may be detected
based on a small panel of VOCs [17]. This concept
was recently translated in vivo: ventilated patients
with and without positive bacterial cultures of endo-
tracheal aspirate could be discriminated based on
exhaled VOCs [24].
The aim of this study is to determine whether molecular
analysis of breath can be used to discriminate between
patients that are suspected of VAP who have positive
cultures and who have negative cultures with high sensi-
tivity, thus having the potential to limit antibiotic use.
Secondly, we hypothesize that molecular analysis of breath
can be used to specifically detect the causative pathogen
in patients that are suspected of VAP, offering the possibil-
ity of more targeted antibiotic therapy.
Methods
Design
‘BreathDx – Molecular Analysis of Exhaled Breath as Diag-
nostic Test for Ventilator–Associated Pneumonia’ is an
international European multicentre observational cohort
study in intubated and ventilated ICU patients suspected of
VAP. Six ICUs of university hospitals in the Netherlands,
the United Kingdom, Spain and Portugal are involved: the
Academic Medical Centre (AMC) in Amsterdam; University
Hospital South Manchester (UHSM), Salford Royal and
Central Manchester University Hospitals in Manchester;
Parc Tauli Hospital in Sabadell; and Sao Francisco Hospital/
Nova Medical School in Lisbon. Patients are expected to be
recruited from all six sites over an 18 to 24-month time
period. The project is funded by the European Union
(BreathDx – 611951).
Study population
Patients at one of the six involved ICUs that are clinically
suspected of having VAP are eligible for the study. VAP is
defined by (1) systemic changes [temperature >38 or
<36.5 °C; white blood cell count <4,000 or >12,000/mm3];
and (2) chest abnormalities [new infiltrates on chest
X-ray, purulent tracheal secretions]; and (3) positive
microbiology results [25]. Inclusion criteria are (1) 18 years
and older and (2) intubation and mechanical ventilation
for > 48 h and (3) clinical suspicion of VAP (aforemen-
tioned systemic changes combined with chest abnormal-
ities). Exclusion criteria include patients who: (1) are
deemed clinically inappropriate to collect samples from
(e.g. if they are receiving end-of-life care); or (2) are in
strict isolation (e.g. Middle East Respiratory Syndrome,
Ebola or resistant tuberculosis).
Study procedures
Patients will be recruited and samples collected within
24 h of the clinical suspicion of VAP. First breath sam-
ples will be collected, followed by bronchoscopy and
bronchial lavage. Standard Operating Procedures (SOPs)
will be in place at all sites in order to ensure samples are
collected equally. Breath samples will be shipped within
days after collection and shall be analysed within 2 weeks
upon arrival. Previous results have shown breath sam-
ples can be stored for at least 14 days without loss of
data [26]. The (mini) BAL samples are processed and
frozen immediately after recruitment. When all (mini)
BAL samples are collected they will be shipped on dry
ice to remain conserved.
Breath sampling
Breath samples will be collected once (at time of recruit-
ment) using a breath gas sampler (BGS, see Fig. 1) consist-
ing of a pump (NMS020B 6VDC Micro Membranegas
pump), a mass flow controller (Horiba STEC Z500), battery
and charger (Panasonic LC-RA1212PG and IDEAL
POWER PC170-2) all combined in a metal casing with op-
erating display (Brooks Instrument 0254). Using this BGS
and PTFE (PolyTetraFluoroEthylene) tubing (Swagelok,
Warrington, UK), the exhaled breath is drawn from the
sidearm of a T-piece connector inserted in the ventilator
circuit distal of the HME filter and through a stainless steel
sorbent tube (Markes International, Llantrisant, UK; and
Gerstel, Mülheim an der Ruhr, Germany), adapted from
Bos et al [23]. Subsequently the sorbent tubes will be trans-
ported for off-site analysis. The samples will be link-
anonymised. Two pairs will be collected per patient and
will be sent to two different laboratory locations for analysis
(one pair to Philips Research, Eindhoven, the Netherlands
and the other to Manchester Institute of Biotechnology,
University of Manchester, Manchester, United Kingdom).
For analysis at Philips Research the exhaled breath is
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collected using sorbent tubes packed with 300 mg
Carbograph 5TD (Markes International, Llantrisant,
UK) and 90 mg Tenax GR (Sigma-Aldrich Chemie
B.V., Zwijndrecht, the Netherlands). The samples to be
analysed at the Manchester Institute of Biotechnology are
collected using sorbent tubes packed with 200 mg Tenax
GR (Markes International, Llantrisant, UK). All samples
are taken in duplicate. Breath samples are stored in a cold
room immediately after collection. This sampling setup
has shown to be safe and adequate for sample collection
in ventilated ICU patients [18, 23, 27].
Bronchoalveolar lavage
A (mini)-BAL sample will be obtained for microbiological
analysis as soon as possible after collecting the breath sam-
ples (see Fig. 2). A syringe is connected to a bronchoscope
or a 50 cm suctioning catheter and 20 mL 0.9% saline is
injected in the airway. At least 4 mL is aspirated of which
1 mL is sent to the medical microbiology for routine
cultures, leading to a semi-quantitative bacterial count with
a cut-off of 104 colony forming units/mL defining a positive
culture. An aliquot of the (mini)-BAL sample will be
processed and stored for future analysis.
Fig. 2 Overview of the sample collection
Fig. 1 The breath gas sampler
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Gas chromatography and mass-spectrometry
The exhaled breath sample will be analysed using Thermal
Desorption – Gas Chromatography – Mass-Spectrometry
(TD-GC-MS). In order to separate, quantify and identify a
wide range of volatiles in breath, different chromato-
graphic set-ups at Eindhoven and Manchester are used.
Both GC-MS analyses will result in a list of detected
volatiles and their relative concentrations.
At Philips Research, the sorbent tubes are thermally
desorbed at 225 °C (TDSA, Gerstel, Mülheim an der
Ruhr, Germany) into the GC capillary column. Solvent
venting mode is used to transfer the sample without loss
to the packed liner (filled with Tenax TA) held at −55 °C
which is subsequently heated to 280 °C. A cold trap
(CTS2, Gerstel, Mülheim an der Ruhr, Germany) is
used to minimize band broadening (initial temperature
−150 °C, after 1.6 min heated to 220 °C). A capillary
gas chromatograph (6890 N GC, Agilent, SantaClara,
CA, USA) using a VF1-MS column (length 30 m × in-
ternal diameter 0.25 mm, film thickness 1 μm, 100%
dimethyl-polysiloxane, Varian Chrompack, Middelburg,
the Netherlands) is used with the following temperature
program: 30 °C-hold 3.5 min, ramp 5 °C/min to 50 °C,
hold 0 min, ramp 10 °C/min to 90 °C, ramp 15 °C/min
to 130 °C, ramp 30 °C/min to 180 °C, ramp 40 °C/min
to 280 °C, hold 1 min. A Time-of-Flight Mass Spec-
trometer (Pegasus 4D system, LECO, St. Joseph, Mi,
USA) is used in the electron ionization mode at 70 eV,
with a scan range of m/z 29–400 Da, scanning rate 20
scans/s. Gaseous calibration standards (10 ppmv
acetone-D8, hexane-D14, toluene-D8, xylene-D10 in ni-
trogen, Air Products, Amsterdam, the Netherlands) are
made by use of a home-built dilution system and
loaded on adsorption tubes as an internal standard.
At Manchester Institute of Biotechnology sorbent
tubes filled with Tenax GR are thermally desorbed at
280 °C (TD100, Markes International, Llantrisant, UK)
into a cold trap to minimize band broadening (initial
temperature −0 °C, after 2 min heated again to 280 °C).
This will then be fed into a capillary gas chromatograph
(7890B GC, Agilent, SantaClara, CA, USA) using a
HP-5 ms Ultra Inert column (length 30 m × internal
diameter 0.25 mm, film thickness 0.25 μm, (5%-
Phenyl)-methylpolysiloxane, Agilent, SantaClara, CA,
USA) with the following temperature program: 40 °C -
hold 0 min, ramp 6 °C/min to 170 °C, hold 0 min, ramp
15 °C/min to 190 °C for a total time of 23 min. A Triple-
Quad mass spectrometer (7010, Agilent, SantaClara, CA,
USA) will be used in the electron ionization mode at
70 eV, with a scan range of m/z 40–500 Da, scanning rate
4 scans/s. A gaseous calibration standard (1 ppmv, 4-
Bromofluorobenzene in nitrogen, Thames Restek, UK)
will be loaded on adsorption tubes as an internal standard
for 1 min at 20 ml/min. Additionally, to aid in retention
time correction, an external standard containing a mixture
of laboratory standard VOC chemicals (Sigma Aldrich,
UK) will be sampled on separate tubes, either side of a
breath sample.
Clinical data
Clinical data regarding patient characteristics, primary
and secondary diagnoses, comorbidities, drug history,
measures of disease severity such as Acute Physiology
and Chronic Health Evaluation (APACHE) IV [28] and
Simplified Acute Physiology Score (SAPS) II [29] ventila-
tion data, CPIS [10], culture data, outcome variables
(ICU/hospital length of stay, mortality) and adverse
events will be collected.
Study outcomes
The primary endpoint is the accuracy of cross-validated
prediction for positive respiratory cultures in patients
that are suspected of VAP, with a sensitivity of at least
99% (high negative predictive value).
The secondary endpoints are: (1) the accuracy of
cross-validated prediction for growth of a specific patho-
gen with a specificity of at least 90%; (2) GC-MS identi-
fied molecular markers that can distinguish between
patients with and without microbiologically confirmed
VAP with p <0.05 and a false discovery rate <0.05; (3)
GC-MS identified molecular markers that can distin-
guish between patients with and without growth of
specific pathogens during bacterial culture with p <0.05
and a false discovery rate <0.05; (4) accuracy of predic-
tion within the subgroup of patients with and without a
previous respiratory infection; (5) accuracy of prediction
within the subgroup of patients intubated for less and
more than 1 week.
Sample size calculation
The sample size calculation has been performed based
on binomial distributions instead of normal approxima-
tions to this distribution [30]. With an expected sensitiv-
ity of 99% (almost 100% negative predictive value) we
require the lower 95% confidence limit to be larger than
90% with 95% probability. 90% sensitivity is the absolute
minimal in a discovery study such as this, for a lower
sensitivity is clinically irrelevant and would not be clinic-
ally useful. With these figures, the required number of
cases is estimated to be 61 [30]. Assuming a prevalence
of 40% of positive cultures of bronchoalveolar lavage in
patients that are clinically suspected of VAP [24], the
total study sample size should be 153 subjects.
Statistical analysis
The GC-MS data are three-dimensional in nature, with
ion counts for every combination of m/z value and
retention time. The chromatogram represents the total
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ion count (TIC) measured by GC-MS as a function of
retention time. The first step in pre-processing consists
of correcting the chromatographic baseline, required for
proper estimation of ion intensities and accurate mol-
ecule identification based on the mass spectra. Subse-
quently the data will be visually inspected to exclude
contaminated samples. Contamination of the sampling
tubes (e.g. due to loose fittings during transport) can
severely distort the stored breath content. These tubes
will be excluded from further analysis.
For peak detection we will use the method described
by Smith et al. [31] implemented in the R-package
XCMS [31–33]. It is currently the most cited pre-
processing tool in the metabolomics literature [34]. The
settings for peak detection will be determined as de-
scribed by Smith et al. [31], using model peak widths
that are considerably larger than the signal peak (1.5 – 4
times) for consistent signal-to-noise improvement [35].
The intensity of the internal standards toluene-d8
and 4-bromofluorobenzene will be used to normalize
all other peaks in the GC-MS data of the two
laboratories, respectively.
The retention time alignment in the XCMS package
works very well for relatively small retention time shifts.
For large shifts this method becomes inaccurate result-
ing in the loss of peaks in the final table and erroneous
alignment of the samples. In our experiment the samples
will be measured over a time span of at least 18 months.
Therefore rather large retention time shifts can be
expected. To account for the retention time shifts the
following approach will be applied, which consists of
two steps [27]. First the major part of the time shifts will
be corrected by using anchor points (marker molecules),
i.e. molecules with clearly identifiable mass spectra
distributed over the full retention time window. Exam-
ples are isoprene, toluene and compounds from the
internal standards. These molecules will be identified by
comparing the measured mass spectra to the spectra
published in the National Institute of Standards and
Technology (NIST) chemistry web book database [36]
using the dot-product function as similarity measure.
According to Stein and Scott [37], this algorithm gives
the best similarity estimate between mass spectra. The
first raw retention time correction will be performed
using a linear or quadratic fit to the retention times of
the marker molecules. The second step in the approach
will consist of fine alignment using the regular retention
time correction of the XCMS package, as described by
Smith et al. [31].
All the steps above will result in an ion-fragment peak
table. Each row in the table corresponds with a sample.
The first few columns will contain sample and patient
data, such as sample data, age, gender and illnesses. The
remaining columns will contain the abundances of the
peaks or ion-fragments; typically there are a few thou-
sand. This table will serve as input for extra quality
checks and subsequent statistical analysis.
One of the quality checks will consist of comparing
the two pairs of samples successively collected from each
patient. The content of these duplicates should be
equivalent, especially when compared to the content of
other, arbitrary samples. Cosine similarity measures will
be plotted into the histograms for duplicate samples and
arbitrary samples. The equalities of the distributions in
the histograms will be tested with the two-sided
Kolmogorov–Smirnov test. Additionally the intensity
of several common molecules between replicate sam-
ples will be analysed using Bland-Altman plots.
Samples measured on different GC-MS instruments
are rarely identical due to multiple differing technical
characteristics. Previous attempts to align data from dif-
ferent GC-MS machines have proved to be very compli-
cated. Therefore the samples from different GC-MS
machines will be aligned separately. For each GC-MS
machine fragment averaging over the two consecutive
samples will summarize peak intensities. In this way the
number of breath features becomes roughly twice as
large. Newly added features will be correlated to the
existing features, since they are sequentially sampled
from the same patient. The dependence between the
features and the higher number of features puts higher
strain on the statistical analysis.
The data can now be used for (1) data discovery, (2)
untargeted analysis and (3) targeted analysis. Data
discovery will consist of principle component analysis
(PCA) on the log-transformed and scaled data, and
Ward clustering on the 100 most abundant peaks eluting
at least one second apart, as well as on the most relevant
principle components.
Untargeted analysis will consist of building predictive
models based on the data. The models will reduce the
dimensionality of the dataset: the number of features is
many times higher than the number of patients, increas-
ing the risk of over-fitting. Additionally the features are
not independent: several ion fragments originate from
the same molecule. The statistical model needs to be
able to deal with this. Finally breath data typically shows
large variation in VOC abundance between, but also
within individuals. Considering these characteristics of
the data, we have chosen sparse partial least squares
models to analyse the log-transformed data [38]. The
small number of included patients will not allow data to
be split into a training set and a validation set, although
this is the preferred method. Instead permutation tests
will be used to estimate the performance of the model.
In the targeted approach existing literature will be
searched for potential biomarkers for VAP. The abun-
dance of such molecules will be compared between
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patient groups using student t-tests or Mann–Whitney-
Wilcoxon tests for normally and non-normally distrib-
uted data respectively. The important advantage of this
approach is the low likelihood on false discoveries. The
amount of comparisons is limited and previous findings
will be validated.
In order to assess the influence of possible con-
founders (e.g. comorbidities, ventilator settings, medica-
tions) on the association between exhaled breath and the
VAP the log odds ratios will be compared between a lo-
gistic regression model with the VOCs of interest as
dependent variables and VAP (yes/no) as independent
variable and the same model with the inclusion of the
potential confounder as co-variate. When the log odds
ratio shows a change of more than 10% the co-variate
will be considered a confounder.
End of study definition
The study will end when the required sample size is
reached.
Reporting
The results will be reported strictly following Stan-
dards for Reporting Diagnostic Accuracy (STARD)
guidelines [39].
Discussion
This manuscript describes the protocol for a multicentre
prospective observational study that aims to develop a
diagnostic tool for discriminating between patients that
are suspected of VAP who have positive cultures and
who have negative cultures through breath analysis using
TD-GC-MS. Additionally, we aim to describe patterns of
VOCs in exhaled breath that are predictive of the pres-
ence of specific pathogens. Ultimately we strive for a
diagnostic test with 99% sensitivity for culture positive
VAP, which is required in an ICU setting where delayed
initiation of adequate antibiotic therapy is unacceptable.
Several clinical challenges can be recognized for this
study a priori. First, the reported incidence of VAP has
declined over the last decade [40]. As recruitment
depends on the clinical suspicion of VAP, this could slow
the inclusion rate. The clinical definition for inclusion
into the study could also be seen as a weakness of the
study as clinical practice may vary from hospital to
hospital. However, we have tried to include hospitals
from a wide variety of settings and countries throughout
Europe to cover the heterogeneity in clinical practice.
This geographical variation may also introduce noise
into the data collected by breath analysis as the environ-
ment contributes to exhaled VOCs [41, 42]. Another chal-
lenge concerns the secondary aim of this study to identify
patterns of VOCs that are predictive of the presence of
specific causative pathogens. A number of VOCs are
already associated with certain pathogens. There is a large
number of pathogens that can cause VAP [43] and the
groups of patients are not likely to be infected with the
same pathogen. This is a risk that is inherent to a pro-
spective clinical study. We expect to find sufficiently large
groups of patients for at least the most important patho-
gens in VAP: Pseudomonas aeruginosa, Staphylococcus
aureus and Enterobacteriaceae [43].
There are also multiple analytical challenges. Patients
will be recruited over a minimum 18-month period. As
a result, the GC-MS platforms will have to be stable over
this period of time when there is potential for column
degradation that can change the retention time of VOCs.
Several members of the consortium previously per-
formed studies over similarly long periods of time and
have developed statistical tools to correct for this shift in
retention time [27]. The sensitivity of the mass spec-
trometer may also drift. This was a problem in previous
studies and therefore an internal standard was included
in the present protocol. As in any study that focuses on
breath analysis there is always the challenge of statistical
overfitting [44]. We expect to find several hundreds of
VOCs in the breath of patients. These will be used as
predictors for the presence of VAP. Such a high dimen-
sional predictor matrix easily results in false discovery
and therefore sufficient internal validation measures
must be taken [45]. There, we suggest two approaches in
this protocol. First, we aim to validate previously found
markers. This limits the number of statistical compari-
sons and increases the changes on valid discoveries.
Second, novel biomarkers are discovered using cross-
validation and permutation tests.
The described protocol also has several strengths and
is pragmatic in nature. The studied population is clinic-
ally very relevant as a treatment decision may be influ-
enced by the outcome of the test. Using an unbiased
approach, with patient recruitment in multiple European
countries and breath analysis on multiple GC-MS plat-
forms, this study allows for the development of a test
that is applicable in a wide variety of hospitals. Special
attention was given to analytical versatility; multiple
sorbent beds are used and breath is analysed on two
separate platforms that have complementary analytical
strengths. There is also additional intellectual benefit;
the results may be translated to other patients; the iden-
tified markers may also be studied in patients suspected
of community- or hospital-acquired pneumonia. An-
other possibility for value within the results is the devel-
opment of a continuous breath test that can warn the
clinician that a patient is about to develop pneumonia.
The results from this study will have direct clinical im-
plications. If the sensitivity of 99% is reached while
maintaining a moderate to good specificity, antibiotic
treatment can be withheld from a large proportion of
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VAP-suspected patients. With a prevalence of culture
positive VAP of 40%, 48 out of every 100 patients would
benefit in the scenario that a sensitivity of 99% and a speci-
ficity of 80% is obtained. Antibiotic therapy could be
withheld in four patients in such a case. These figures
improve with increased specificity at the pre-selected sen-
sitivity and a lower prevalence of culture positive VAP.
In conclusion, we hypothesize that breath analysis can
be used for discrimination between VAP suspected
patients with and without microbiological positive
cultures with a high sensitivity, and can be used to
specifically detect the causative strain of bacteria.
Trial status
Patient recruitment for the BreathDx study is cur-
rently ongoing.
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